Analysts have been eager to weigh in on the Healthcare sector with new ratings on Genocea Biosciences (GNCA) and Zynerba Pharmaceuticals (ZYNE).
Genocea Biosciences (GNCA)
In a report released today, Chad Messer from Needham maintained a Buy rating on Genocea Biosciences, with a price target of $7.00. The company’s shares closed last Monday at $2.04.
According to TipRanks.com, Messer is a 4-star analyst with an average return of 8.7% and a 44.8% success rate. Messer covers the Healthcare sector, focusing on stocks such as Phasebio Pharmaceuticals, Aeglea Biotherapeutics, and Ionis Pharmaceuticals.
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Genocea Biosciences with a $7.00 average price target.
See today’s analyst top recommended stocks >>
Zynerba Pharmaceuticals (ZYNE)
Needham analyst Serge Belanger maintained a Hold rating on Zynerba Pharmaceuticals today. The company’s shares closed last Monday at $3.67.
According to TipRanks.com, Belanger is a 2-star analyst with an average return of 0.6% and a 40.6% success rate. Belanger covers the Healthcare sector, focusing on stocks such as Amphastar Pharmaceuticals, Collegium Pharmaceutical, and KalVista Pharmaceuticals.
Currently, the analyst consensus on Zynerba Pharmaceuticals is a Strong Buy with an average price target of $13.00.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Read More on ZYNE:
